Pierre Gourdy

List of Publications by Year in Descending Order

139 papers	6,977 citations	41 h-index	81 g-index
150 ext. papers	8,305 ext. citations	7 avg, IF	5.48 L-index

#	Paper	IF	Citations
139	Segregation of nuclear and membrane-initiated actions of estrogen receptor using genetically modified animals and pharmacological tools. *Molecular and Cellular Endocrinology*, **2022**, 539, 111467	4.4	0
138	COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study.. *Current Diabetes Reports*, **2022**, 22, 53	5.6	5
137	Association of statin and/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study.. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, **2022**, 16, 102484	8.9	0
136	The hepatocyte insulin receptor is required to program the liver clock and rhythmic gene expression.. *Cell Reports*, **2022**, 39, 110674	10.6	0
135	Association Between the Insertion/Deletion Polymorphism and Risk of Lower-Limb Amputation in Patients With Long-Standing Type 1 Diabetes. *Diabetes Care*, **2021**,	14.6	1
134	Influenza vaccination and prognosis for COVID-19 in hospitalized patients with diabetes: Results from the CORONADO study. *Diabetes, Obesity and Metabolism*, **2021**,	6.7	1
133	Glycaemic Control with Insulin Glargine 300 U/mL in Individuals with Type 2 Diabetes and Chronic Kidney Disease: A REALI European Pooled Data Analysis. *Diabetes Therapy*, **2021**, 12, 1159-1174	3.6	2
132	Integrative study of diet-induced mouse models of NAFLD identifies PPARas a sexually dimorphic drug target. *Gut*, **2021**,	19.2	4
131	I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes. *Diabetes Care*, **2021**, 44, 1377-1384	14.6	3
130	La metformine est associ une moindre mortalit chez les patients diab tiques hospitalis s pour la COVID-19. *Medecine Des Maladies Metaboliques*, **2021**, 15, 278-287	0.1	
129	Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: Results from the CORONADO study. *Diabetes Research and Clinical Practice*, **2021**, 175, 108695	7.4	9
128	Gonadal hormonal factors before menopause and incident type 2 diabetes in women: A 22-year follow-up of 83 799 women from the E3N cohort study. *Journal of Diabetes*, **2021**, 13, 330-338	3.8	1
127	Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study. *Diabetes and Metabolism*, **2021**, 47, 101202	5.4	43
126	Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. *Diabetes, Obesity and Metabolism*, **2021**, 23, 391-403	6.7	35
125	Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. *Diabetes and Metabolism*, **2021**, 47, 101216	5.4	36
124	Estetrol prevents Western diet-induced obesity and atheroma independently of hepatic estrogen receptor *American Journal of Physiology - Endocrinology and Metabolism*, **2021**, 320, E19-E29	6	4
123	Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. *Diabetologia*, **2021**, 64, 778-794	10.3	61

122	Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1162-1172	6.7	19
121	Diab□e et COVID-19´: les le□ns de CORONADO. *Medecine Des Maladies Metaboliques*, **2021**, 15, 15-23	0.1	1
120	Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL: Results from the REALI European Pooled Data Analysis. *Diabetes Therapy*, **2021**, 12, 1073-1097	3.6	0
119	Sex disparities in COVID-19 outcomes of inpatients with diabetes: insights from the CORONADO study. *European Journal of Endocrinology*, **2021**, 185, 299-311	6.5	4
118	History of bariatric surgery and COVID 19 outcomes in patients with type 2 diabetes: results from the CORONADO study. *Obesity*, **2021**,	8	1
117	Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. *Diabetes and Metabolism*, **2021**, 47, 101272	5.4	5
116	Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. *Diabetologia*, **2020**, 63, 1500-1515	10.3	442
115	Mutation of Arginine 264 on ER□(Estrogen Receptor Alpha) Selectively Abrogates the Rapid Signaling of Estradiol in the Endothelium Without Altering Fertility. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 2143-2158	9.4	16
114	Sex differences in metabolic regulation and diabetes susceptibility. *Diabetologia*, **2020**, 63, 453-461	10.3	148
113	Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study. *Diabetes Therapy*, **2020**, 11, 147-159	3.6	4
112	Comment on Chen et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care 2020;43:1399-1407. *Diabetes Care*, **2020**, 43, e163-e164	14.6	4
111	Phenotypic Characteristics and Development of a Hospitalization Prediction Risk Score for Outpatients with Diabetes and COVID-19: The DIABCOVID Study. *Journal of Clinical Medicine*, **2020**, 9,	5.1	10
110	The tissue-specific effects of different 17□estradiol doses reveal the key sensitizing role of AF1 domain in ER□activity. *Molecular and Cellular Endocrinology*, **2020**, 505, 110741	4.4	7
109	17□estradiol promotes acute refeeding in hungry mice via membrane-initiated ER□signaling. *Molecular Metabolism*, **2020**, 42, 101053	8.8	11
108	Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the CORONADO Study. *Diabetes Care*, **2020**, 43, e174-e177	14.6	26
107	Blood glucose levels and COVID-19. Reply to Sardu C, D'Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, J□i P et al [letter]. *Diabetologia*, **2020**, 63, 2491-2494	10.3	4
106	Regulation of hepatokine gene expression in response to fasting and feeding: Influence of PPAR-□ and insulin-dependent signalling in hepatocytes. *Diabetes and Metabolism*, **2020**, 46, 129-136	5.4	17
105	Membrane expression of the estrogen receptor ER□s required for intercellular communications in the mammary epithelium. *Development (Cambridge)*, **2020**, 147,	6.6	4

104	Plasma Apelin and Risk of Type 2 Diabetes in a Cohort From the Community. *Diabetes Care*, **2020**, 43, e15-e16	14.6	8
103	Direct comparison of the specialised blood fibrosis tests FibroMeter and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres. *Alimentary Pharmacology and Therapeutics*, **2019**, 50, 1214-1222	6.1	17
102	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. *Diabetes Care*, **2019**, 42, 2262-2271	14.6	82
101	Hepatic PPARs critical in the metabolic adaptation to sepsis. *Journal of Hepatology*, **2019**, 70, 963-973	13.4	26
100	Selective Liver Estrogen Receptor Modulation Prevents Steatosis, Diabetes, and Obesity Through the Anorectic Growth Differentiation Factor 15 Hepatokine in Mice. *Hepatology Communications*, **2019**, 3, 908-924	6	15
99	Pathologies artielles **2019**, 157-168		
98	Diabe **2019**, 143-148		
97	Prise de position de la Soci Francophone du Diabe (SFD) sur la prise en charge mdicamenteuse de lyperglycmie du patient diabique de type 2 2019. *Medecine Des Maladies Metaboliques*, **2019**, 13, 711-732	0.1	12
96	Adaptive Cell Neogenesis in the Adult Mouse in Response to Glucocorticoid-Induced Insulin Resistance. *Diabetes*, **2019**, 68, 95-108	0.9	11
95	Towards optimization of estrogen receptor modulation in medicine. *Pharmacology & Therapeutics*, **2018**, 189, 123-129	13.9	13
94	Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic-euglycaemic clamp. *Diabetes, Obesity and Metabolism*, **2018**, 20, 157-164	6.7	32
93	The effects of periodontal treatment on diabetic patients: The DIAPERIO randomized controlled trial. *Journal of Clinical Periodontology*, **2018**, 45, 1150-1163	7.7	18
92	MFN2-associated lipomatosis: Clinical spectrum and impact on adipose tissue. *Journal of Clinical Lipidology*, **2018**, 12, 1420-1435	4.9	34
91	Estrogen receptor subcellular localization and cardiometabolism. *Molecular Metabolism*, **2018**, 15, 56-69	8.8	28
90	Predominant Role of Nuclear Versus Membrane Estrogen Receptor In Arterial Protection: Implications for Estrogen Receptor Modulation in Cardiovascular Prevention/Safety. *Journal of the American Heart Association*, **2018**, 7,	6	29
89	Associations between hepatic miRNA expression, liver triacylglycerols and gut microbiota during metabolic adaptation to high-fat diet in mice. *Diabetologia*, **2017**, 60, 690-700	10.3	34
88	Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study. *Advances in Therapy*, **2017**, 34, 674-685	4.1	8
87	Selective Activation of Estrogen Receptor Activation Function-1 Is Sufficient to Prevent Obesity, Steatosis, and Insulin Resistance in Mouse. *American Journal of Pathology*, **2017**, 187, 1273-1287	5.8	28

86	Urinary lysophopholipids are increased in diabetic patients with nephropathy. *Journal of Diabetes and Its Complications*, **2017**, 31, 1103-1108	3.2	14
85	Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications. *Physiological Reviews*, **2017**, 97, 1045-1087	47.9	183
84	Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index. *Diabetes/Metabolism Research and Reviews*, **2017**, 33, e2897	7.5	8
83	Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l'hyperglycémie du patient diabétique de type 2. *Medecine Des Maladies Metaboliques*, **2017**, 11, 577-593	0.1	34
82	Sécurité cardiovasculaire des agonistes du récepteur du glucagon-like peptide-1 et des inhibiteurs du co-transporteur sodium-glucose de type 2 : focus sur les résultats des grands essais d'intervention. *Medecine Des Maladies Metaboliques*, **2017**, 11, 2S27-2S36	0.1	
81	Nuclear and Membrane Actions of Estrogen Receptor Alpha: Contribution to the Regulation of Energy and Glucose Homeostasis. *Advances in Experimental Medicine and Biology*, **2017**, 1043, 401-426	3.6	8
80	Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. *Obesity Reviews*, **2017**, 18, 86-98	10.6	36
79	Urinary and genital infections in patients with diabetes: How to diagnose and how to treat. *Diabetes and Metabolism*, **2016**, 42, 16-24	5.4	11
78	Efficacité et taux de maintenance du liraglutide chez les patients diabétiques de type 2 en pratique clinique courante en France étude EVIDENCE : Une étude observationnelle, prospective, post-commercialisation, avec un suivi de 2 ans. *Medecine Des Maladies Metaboliques*, **2016**, 10, 341-347	0.1	1
77	Association of environmental markers with childhood type 1 diabetes mellitus revealed by a long questionnaire on early life exposures and lifestyle in a case-control study. *BMC Public Health*, **2016**, 16, 1021	4.1	8
76	Glucose Profiles in Pregnant Women After a Gastric Bypass : Findings from Continuous Glucose Monitoring. *Obesity Surgery*, **2016**, 26, 2150-2155	3.7	28
75	Death, end-stage renal disease and renal function decline in patients with diabetic nephropathy in French cohorts of type 1 and type 2 diabetes. *Diabetologia*, **2016**, 59, 208-216	10.3	31
74	Estrogen Therapy Delays Autoimmune Diabetes and Promotes the Protective Efficiency of Natural Killer T-Cell Activation in Female Nonobese Diabetic Mice. *Endocrinology*, **2016**, 157, 258-67	4.8	15
73	Calcineurin Inhibitors Downregulate HNF-1β and May Affect the Outcome of HNF1B Patients After Renal Transplantation. *Transplantation*, **2016**, 100, 1970-8	1.8	3
72	Effets indésirables et sécurité d'emploi des inhibiteurs des SGLT2. *Medecine Des Maladies Metaboliques*, **2015**, 9, S41-S48	0.1	2
71	The Activation Function-1 of Estrogen Receptor Alpha Prevents Arterial Neointima Development Through a Direct Effect on Smooth Muscle Cells. *Circulation Research*, **2015**, 117, 770-8	15.7	35
70	From the Women's Health Initiative to the combination of estrogen and selective estrogen receptor modulators to avoid progestin addition. *Maturitas*, **2015**, 82, 274-7	5	16
69	Association Between Diabetic Macular Edema and Cardiovascular Events in Type 2 Diabetes Patients: A Multicenter Observational Study. *Medicine (United States)*, **2015**, 94, e1220	1.8	9

68	Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study. *Advances in Therapy*, **2015**, 32, 838-53	4.1	29
67	Mutation of the palmitoylation site of estrogen receptor α in vivo reveals tissue-specific roles for membrane versus nuclear actions. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E283-90	11.5	179
66	The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor α modulation, uncoupling nuclear and membrane activation. *EMBO Molecular Medicine*, **2014**, 6, 1328-46	12	59
65	Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes. *Diabetes/Metabolism Research and Reviews*, **2014**, 30, 742-8	7.5	12
64	GLP-1-based strategies: a physiological analysis of differential mode of action. *Physiology*, **2014**, 29, 108-21	3.8	12
63	Prevention of obesity and insulin resistance by estrogens requires ERα activation function-2 (ERαAF-2), whereas ERαAF-1 is dispensable. *Diabetes*, **2013**, 62, 4098-108	0.9	64
62	Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes. *Cellular Signalling*, **2013**, 25, 570-9	4.9	49
61	In vivo dissection of the estrogen receptor alpha: uncoupling of its physiological effects and medical perspectives. *Annales DiEndocrinologie*, **2013**, 74, 82-9	1.7	9
60	Lessons from the dissection of the activation functions (AF-1 and AF-2) of the estrogen receptor alpha in vivo. *Steroids*, **2013**, 78, 576-82	2.8	36
59	Diabetes and oral contraception. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2013**, 27, 67-76	6.5	27
58	Tamoxifen elicits atheroprotection through estrogen receptor α AF-1 but does not accelerate reendothelialization. *American Journal of Pathology*, **2013**, 183, 304-12	5.8	20
57	Vaginal lubrication after cervicovaginal stimulation is facilitated by phosphodiesterase type 5 inhibition in ovariectomized mice. *Journal of Sexual Medicine*, **2013**, 10, 1452-60	1.1	7
56	The AF-1 activation function of estrogen receptor α is necessary and sufficient for uterine epithelial cell proliferation in vivo. *Endocrinology*, **2013**, 154, 2222-33	4.8	52
55	Influence of sildenafil on micturition and urethral tone in ovariectomized and non-ovariectomized mice. *Journal of Sexual Medicine*, **2012**, 9, 466-71	1.1	2
54	The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor α signaling. *Blood*, **2012**, 119, 454-64	2.2	194
53	Chronic estradiol treatment reduces platelet responses and protects mice from thromboembolism through the hematopoietic estrogen receptor α *Blood*, **2012**, 120, 1703-12	2.2	37
52	Structure-function relationship of estrogen receptors in cardiovascular pathophysiological models. *Thrombosis Research*, **2012**, 130 Suppl 1, S7-11	8.2	11
51	Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. *Diabetes and Metabolism*, **2012**, 38, 113-27	5.4	37

50	Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology. *Annales DiEndocrinologie*, **2012**, 73, 469-87	1.7	16
49	High-fat diet induces periodontitis in mice through lipopolysaccharides (LPS) receptor signaling: protective action of estrogens. *PLoS ONE*, **2012**, 7, e48220	3.7	49
48	From in vivo gene targeting of oestrogen receptors to optimization of their modulation in menopause. *British Journal of Pharmacology*, **2012**, 165, 57-66	8.6	13
47	Timing of the vascular actions of estrogens in experimental and human studies: why protective early, and not when delayed?. *Maturitas*, **2011**, 68, 165-73	5	55
46	GLP-1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies **2011**, 279-325		
45	A natural protective function of invariant NKT cells in a mouse model of innate-cell-driven lung inflammation. *European Journal of Immunology*, **2011**, 41, 299-305	6.1	24
44	Estradiol administration controls eosinophilia through estrogen receptor-alpha activation during acute peritoneal inflammation. *Journal of Leukocyte Biology*, **2011**, 90, 145-54	6.5	19
43	Activation function 2 (AF2) of estrogen receptor-alpha is required for the atheroprotective action of estradiol but not to accelerate endothelial healing. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 13311-6	11.5	96
42	17Beta-estradiol promotes TLR4-triggered proinflammatory mediator production through direct estrogen receptor alpha signaling in macrophages in vivo. *Journal of Immunology*, **2010**, 185, 1169-76	5.3	163
41	Estrogen receptors and endothelium. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 1506-12	5.4	143
40	Internalization of microparticles by endothelial cells promotes platelet/endothelial cell interaction under flow. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 2810-9	15.4	79
39	Endothelial estrogen receptor-alpha plays a crucial role in the atheroprotective action of 17beta-estradiol in low-density lipoprotein receptor-deficient mice. *Circulation*, **2009**, 120, 2567-76	16.7	76
38	Estrogen receptor alpha expression in both endothelium and hematopoietic cells is required for the accelerative effect of estradiol on reendothelialization. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 1543-50	9.4	41
37	The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta-estradiol. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 2053-8	11.5	99
36	The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. *European Journal of Immunology*, **2009**, 39, 1046-55	6.1	254
35	Periodontal treatment to improve glycaemic control in diabetic patients: study protocol of the randomized, controlled DIAPERIO trial. *Trials*, **2009**, 10, 65	2.8	15
34	Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. *Endocrinology*, **2009**, 150, 2109-17	4.8	302
33	Prevention of skin flap necrosis by estradiol involves reperfusion of a protected vascular network. *Circulation Research*, **2009**, 104, 245-54, 12p following 254	15.7	45

32	Efficacy of periodontal treatment on glycaemic control in diabetic patients: A meta-analysis of interventional studies. *Diabetes and Metabolism*, **2008**, 34, 497-506	5.4	147
31	The estrogen effects on endothelial repair and mitogen-activated protein kinase activation are abolished in endothelial nitric-oxide (NO) synthase knockout mice, but not by NO synthase inhibition by N-nitro-L-arginine methyl ester. *American Journal of Pathology*, **2008**, 172, 830-8	5.8	24
30	Estradiol increases urethral tone through the local inhibition of neuronal nitric oxide synthase expression. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2008**, 294, R851-7	3.2	20
29	Estradiol accelerates endothelial healing through the retrograde commitment of uninjured endothelium. *American Journal of Physiology - Heart and Circulatory Physiology*, **2008**, 294, H2822-30	5.2	30
28	Chronic estradiol administration in vivo promotes the proinflammatory response of macrophages to TLR4 activation: involvement of the phosphatidylinositol 3-kinase pathway. *Journal of Immunology*, **2008**, 180, 7980-8	5.3	123
27	Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. *Circulation*, **2008** , 117, 1310-7	16.7	110
26	Estrogen receptor alpha, but not beta, is required for optimal dendritic cell differentiation and [corrected] CD40-induced cytokine production. *Journal of Immunology*, **2008**, 180, 3661-9	5.3	72
25	Role of human smooth muscle cell progenitors in atherosclerotic plaque development and composition. *Cardiovascular Research*, **2008**, 77, 471-80	9.9	73
24	Effect of raloxifene -- a selective oestrogen receptor modulator -- on kidney function in post-menopausal women with Type 2 diabetes: results from a randomized, placebo-controlled pilot trial. *Diabetic Medicine*, **2007**, 24, 906-10	3.5	27
23	Transforming growth factor activity is a key determinant for the effect of estradiol on fatty streak deposit in hypercholesterolemic mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 2214-21	9.4	12
22	The Pro-Th1 cytokine IL-12 enhances IL-4 production by invariant NKT cells: relevance for T cell-mediated hepatitis. *Journal of Immunology*, **2007**, 178, 5435-42	5.3	33
21	Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 2691-8	9.4	123
20	Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity. *Gut*, **2007**, 56, 107-14	19.2	15
19	Measles virus nucleoprotein induces a regulatory immune response and reduces atherosclerosis in mice. *Circulation*, **2007**, 116, 1707-13	16.7	33
18	Estrogens in vascular biology and disease: where do we stand today?. *Current Opinion in Lipidology*, **2007**, 18, 554-60	4.4	55
17	Essential role of bone marrow fibroblast growth factor-2 in the effect of estradiol on reendothelialization and endothelial progenitor cell mobilization. *American Journal of Pathology*, **2006**, 169, 1855-62	5.8	37
16	Understanding the oestrogen action in experimental and clinical atherosclerosis. *Fundamental and Clinical Pharmacology*, **2006**, 20, 539-48	3.1	23
15	Natural regulatory T cells control the development of atherosclerosis in mice. *Nature Medicine*, **2006**, 12, 178-80	50.5	786

14	The atheroprotective effect of 17beta-estradiol depends on complex interactions in adaptive immunity. *American Journal of Pathology*, **2005**, 167, 267-74	5.8	18
13	Relevance of sexual dimorphism to regulatory T cells: estradiol promotes IFN-gamma production by invariant natural killer T cells. *Blood*, **2005**, 105, 2415-20	2.2	116
12	Role of fibroblast growth factor-2 isoforms in the effect of estradiol on endothelial cell migration and proliferation. *Circulation Research*, **2004**, 94, 1301-9	15.7	52
11	Estrogens and atherosclerosis. *European Journal of Endocrinology*, **2004**, 150, 113-7	6.5	38
10	Deleting TCR alpha beta+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice. *American Journal of Pathology*, **2004**, 165, 2013-8	5.8	94
9	Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice. *Blood*, **2003**, 102, 4052-8	2.2	119
8	Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. *European Journal of Immunology*, **2003**, 33, 512-21	6.1	195
7	The atheroprotective effect of 17 beta-estradiol is not altered in P-selectin- or ICAM-1-deficient hypercholesterolemic mice. *Atherosclerosis*, **2003**, 166, 41-8	3.1	17
6	Protective role of uncoupling protein 2 in atherosclerosis. *Circulation*, **2003**, 107, 388-90	16.7	210
5	Eating frequency and body fatness in middle-aged men. *International Journal of Obesity*, **2002**, 26, 1476-83	5.5	59
4	Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. *Diabetes Care*, **2002**, 25, 1371-7	14.6	113
3	Failure of L-nitroarginine to inhibit the activity of aortic inducible nitric oxide synthase. *Journal of Vascular Research*, **2001**, 38, 266-75	1.9	8
2	Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. *Atherosclerosis*, **2001**, 155, 291-5	3.1	16
1	ATGL-dependent white adipose tissue lipolysis controls hepatocyte PPAR□activity		1